Genmor Pharmaceuticals' Acquisition of Vascorex Corporation Net Present Value (NPV) / MBA Resources

Introduction to Net Present Value (NPV) - What is Net Present Value (NPV) ? How it impacts financial decisions regarding project management?

NPV solution for Genmor Pharmaceuticals' Acquisition of Vascorex Corporation case study

At Oak Spring University, we provide corporate level professional Net Present Value (NPV) case study solution. Genmor Pharmaceuticals' Acquisition of Vascorex Corporation case study is a Harvard Business School (HBR) case study written by Robert F. Bruner, Paul Simko, Mary Margaret Frank, Marc Goldstein. The Genmor Pharmaceuticals' Acquisition of Vascorex Corporation (referred as “Ip Acquisition” from here on) case study provides evaluation & decision scenario in field of Finance & Accounting. It also touches upon business topics such as - Value proposition, Intellectual property, Mergers & acquisitions.

The net present value (NPV) of an investment proposal is the present value of the proposal’s net cash flows less the proposal’s initial cash outflow. If a project’s NPV is greater than or equal to zero, the project should be accepted.

NPV = Present Value of Future Cash Flows LESS Project’s Initial Investment

---

Case Description of Genmor Pharmaceuticals' Acquisition of Vascorex Corporation Case Study

This case asks students to identify and evaluate the merits of two factors that have led a buy-side analyst to conclude that an acquiring company is a high-risk investment: (1) the company's allocation of acquisition proceeds and (2) the quality of the target's intellectual-property (IP) portfolio. The acquirer's allocation of the acquisition cost of the target is quite different from that of one of the company's previous deals. Careful interpretation of each line item for both acquisitions yields insights into the value management seeks with the acquisition. An IP-quality report supplied by an independent IP consulting firm likewise raises a number of issues students should identify. The primary objectives of the case are to (1) introduce IP-quality concepts as they relate to a firm's patent portfolio, (2) understand the accounting basis for firms' purchase-price allocations in IP-intensive acquisitions, and (3) compare and contrast the risk implications of acquisitions of in-process portfolios of drug candidates with established products.

Case Authors : Robert F. Bruner, Paul Simko, Mary Margaret Frank, Marc Goldstein

Topic : Finance & Accounting

Related Areas : Intellectual property, Mergers & acquisitions

---

Calculating Net Present Value (NPV) at 6% for Genmor Pharmaceuticals' Acquisition of Vascorex Corporation Case Study

Years	Cash Flow	Net Cash Flow	Cumulative     Cash Flow	Discount Rate @ 6 %	Discounted Cash Flows
Year 0	(10000887)	-10000887	-	-
Year 1	3444618	-6556269	3444618	0.9434	3249640
Year 2	3953555	-2602714	7398173	0.89	3518650
Year 3	3948188	1345474	11346361	0.8396	3314975
Year 4	3237981	4583455	14584342	0.7921	2564784
TOTAL			14584342		12648049

The Net Present Value at 6% discount rate is 2647162

In isolation the NPV number doesn't mean much but put in right context then it is one of the best method to evaluate project returns. In this article we will cover -

Different methods of capital budgeting

What is NPV & Formula of NPV,
How it is calculated,
How to use NPV number for project evaluation, and
Scenario Planning given risks and management priorities.

---

Capital Budgeting Approaches

Methods of Capital Budgeting

There are four types of capital budgeting techniques that are widely used in the corporate world –

1. Profitability Index
2. Net Present Value
3. Payback Period
4. Internal Rate of Return

Apart from the Payback period method which is an additive method, rest of the methods are based on Discounted Cash Flow technique. Even though cash flow can be calculated based on the nature of the project, for the simplicity of the article we are assuming that all the expected cash flows are realized at the end of the year.

Discounted Cash Flow approaches provide a more objective basis for evaluating and selecting investment projects. They take into consideration both –

1. Magnitude of both incoming and outgoing cash flows – Projects can be capital intensive, time intensive, or both. Ip Acquisition shareholders have preference for diversified projects investment rather than prospective high income from a single capital intensive project.
2. Timing of the expected cash flows – stockholders of Ip Acquisition have higher preference for cash returns over 4-5 years rather than 10-15 years given the nature of the volatility in the industry.

---

Formula and Steps to Calculate Net Present Value (NPV) of Genmor Pharmaceuticals' Acquisition of Vascorex Corporation

NPV = Net Cash In Flowt1 / (1+r)t1 + Net Cash In Flowt2 / (1+r)t2 + … Net Cash In Flowtn / (1+r)tn
Less Net Cash Out Flowt0 / (1+r)t0

Where t = time period, in this case year 1, year 2 and so on.
r = discount rate or return that could be earned using other safe proposition such as fixed deposit or treasury bond rate. Net Cash In Flow – What the firm will get each year.
Net Cash Out Flow – What the firm needs to invest initially in the project.

Step 1 – Understand the nature of the project and calculate cash flow for each year.
Step 2 – Discount those cash flow based on the discount rate.
Step 3 – Add all the discounted cash flow.
Step 4 – Selection of the project

Why Finance & Accounting Managers need to know Financial Tools such as Net Present Value (NPV)?

In our daily workplace we often come across people and colleagues who are just focused on their core competency and targets they have to deliver. For example marketing managers at Ip Acquisition often design programs whose objective is to drive brand awareness and customer reach. But how that 30 point increase in brand awareness or 10 point increase in customer touch points will result into shareholders’ value is not specified.

To overcome such scenarios managers at Ip Acquisition needs to not only know the financial aspect of project management but also needs to have tools to integrate them into part of the project development and monitoring plan.

Calculating Net Present Value (NPV) at 15%

After working through various assumptions we reached a conclusion that risk is far higher than 6%. In a reasonably stable industry with weak competition - 15% discount rate can be a good benchmark.

Years	Cash Flow	Net Cash Flow	Cumulative     Cash Flow	Discount Rate @ 15 %	Discounted Cash Flows
Year 0	(10000887)	-10000887	-	-
Year 1	3444618	-6556269	3444618	0.8696	2995320
Year 2	3953555	-2602714	7398173	0.7561	2989456
Year 3	3948188	1345474	11346361	0.6575	2595998
Year 4	3237981	4583455	14584342	0.5718	1851326
TOTAL					10432099

The Net NPV after 4 years is 431212

(10432099 - 10000887 )

---

Calculating Net Present Value (NPV) at 20%

If the risk component is high in the industry then we should go for a higher hurdle rate / discount rate of 20%.

Years	Cash Flow	Net Cash Flow	Cumulative     Cash Flow	Discount Rate @ 20 %	Discounted Cash Flows
Year 0	(10000887)	-10000887	-	-
Year 1	3444618	-6556269	3444618	0.8333	2870515
Year 2	3953555	-2602714	7398173	0.6944	2745524
Year 3	3948188	1345474	11346361	0.5787	2284831
Year 4	3237981	4583455	14584342	0.4823	1561526
TOTAL					9462397

The Net NPV after 4 years is -538490

At 20% discount rate the NPV is negative (9462397 - 10000887 ) so ideally we can't select the project if macro and micro factors don't allow financial managers of Ip Acquisition to discount cash flow at lower discount rates such as 15%.

Acceptance Criteria of a Project based on NPV

Simplest Approach – If the investment project of Ip Acquisition has a NPV value higher than Zero then finance managers at Ip Acquisition can ACCEPT the project, otherwise they can reject the project. This means that project will deliver higher returns over the period of time than any alternate investment strategy.

In theory if the required rate of return or discount rate is chosen correctly by finance managers at Ip Acquisition, then the stock price of the Ip Acquisition should change by same amount of the NPV. In real world we know that share price also reflects various other factors that can be related to both macro and micro environment.

In the same vein – accepting the project with zero NPV should result in stagnant share price. Finance managers use discount rates as a measure of risk components in the project execution process.

Sensitivity Analysis

Project selection is often a far more complex decision than just choosing it based on the NPV number. Finance managers at Ip Acquisition should conduct a sensitivity analysis to better understand not only the inherent risk of the projects but also how those risks can be either factored in or mitigated during the project execution. Sensitivity analysis helps in –

What can impact the cash flow of the project.

What are the key aspects of the projects that need to be monitored, refined, and retuned for continuous delivery of projected cash flows.

Understanding of risks involved in the project.

What will be a multi year spillover effect of various taxation regulations.

What are the uncertainties surrounding the project Initial Cash Outlay (ICO’s). ICO’s often have several different components such as land, machinery, building, and other equipment.

Some of the assumptions while using the Discounted Cash Flow Methods –

Projects are assumed to be Mutually Exclusive – This is seldom the came in modern day giant organizations where projects are often inter-related and rejecting a project solely based on NPV can result in sunk cost from a related project.

Independent projects have independent cash flows – As explained in the marketing project – though the project may look independent but in reality it is not as the brand awareness project can be closely associated with the spending on sales promotions and product specific advertising.

---

Negotiation Strategy of Genmor Pharmaceuticals' Acquisition of Vascorex Corporation

References & Further Readings

Robert F. Bruner, Paul Simko, Mary Margaret Frank, Marc Goldstein (2018), "Genmor Pharmaceuticals' Acquisition of Vascorex Corporation Harvard Business Review Case Study. Published by HBR Publications.